Several pieces of evidence suggest that S1P signaling in these cell populations might be relevant to the progression of the disease, opening up new perspectives for drugs acting on the S1P axis in the therapy of MS (reviewed in Groves et al., 2013; Farez and Correale, 2016). Here, MBTPS1 is linked to myeloid sarcoma.